Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer
NCT00645177
Completed
The purpose of this study is to determine the effect of ABT-869 plus paclitaxel compared to paclitaxel alone on disease progression in metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/23/2013
Locations: Site Reference ID/Investigator# 8352, San Francisco, California
Conditions: Metastatic Breast Cancer
Register for Updates
S9912 Combination Chemo in Stage III Ovarian Cancer,
NCT00003896
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, cisplatin, and liposomal doxorubicin in treating women who have undergone surgery for stage III ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
01/02/2013
Locations: University of California Davis Cancer Center, Davis, California +7 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00085501
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining more than one chemotherapy drug with a monoclonal antibody may kill more tumor cells. It is not yet known whether cetuximab is more effective when given at the same time a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2012
Locations: Alta Bates Comprehensive Cancer Center, Berkeley, California +18 locations
Conditions: Lung Cancer
Register for Updates
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
NCT01161186
Completed
The purpose of this study is to evaluate optimal dose and safety of the combination of Abraxane, gemcitabine, and Xeloda (capecitabine) (AGX) as first-line therapy in patients with metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2012
Locations: UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California
Conditions: Pancreatic Neoplasms, Pancreatic Cancer, Adenocarcinoma
Register for Updates
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
NCT00307047
Completed
The purpose of the SPIRIT IV Clinical Trial is to continue to evaluate the safety and efficacy of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V®). The XIENCE V® arm will be compared to an active control, represented by the FDA-approved TAXUS® EXPRESS2™ Paclitaxel-Eluting Coronary Stent System (TAXUS®), commercially available from Boston Scientific. TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent System is manufactured by Boston Scientific.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2012
Locations: Inova Fairfax Hospital, Fairfax, California +5 locations
Conditions: Coronary Artery Disease
Register for Updates
S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00003587
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of two different combination chemotherapy regimens in treating patients who have stage IIIB or stage IV non-small cell lung cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2012
Locations: Beckman Research Institute, City of Hope, Duarte, California +9 locations
Conditions: Lung Cancer
Register for Updates
Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer
NCT00284752
Completed
Evaluate the efficacy of Abraxane in first line chemotherapy of patients with hormone refractory metastatic prostate cancer, based on prostate specific antigen (PSA) response
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/28/2012
Locations: Kaiser Permanente, Vallejo, California
Conditions: Prostate Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer
NCT00003072
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells. PURPOSE: Randomized phase II double-blinded trial to study the effectiveness of paclitaxel and carboplatin given with either amifostine or placebo in patients with metastatic stage III or stage IV ovarian cancer or metastatic stage III or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2012
Locations: Oncology Service of San Francisco General Hospital Medical Center, San Francisco, California +3 locations
Conditions: Lung Cancer, Neurotoxicity, Ovarian Cancer
Register for Updates
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
NCT00373256
Completed
To compare treatment with SU011248 plus paclitaxel versus bevacizumab plus paclitaxel to determine which treatment works better against breast cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/05/2012
Locations: Pfizer Investigational Site, Anaheim, California +40 locations
Conditions: Breast Neoplasms
Register for Updates
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
NCT00085839
Completed
The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. The study will also evaluate the safety of single-agent erlotinib in this patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: California Cancer Care, Inc., Greenbrae, California +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00294762
Completed
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway. The study will assess prospectively the efficacy of erlotinib as a single agent or intercalated with chemotherapy in highly selected patients with EGFR overexpression and/or EGFR amplification.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2012
Locations: Central Hematology Oncology Medical Group Inc., Alhambra, California +11 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00002969
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with paclitaxel in treating patients with stage IIIB or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/20/2012
Locations: Beckman Research Institute, City of Hope, Duarte, California +9 locations
Conditions: Lung Cancer
Register for Updates